



Short communication

Molecular characterization of a clinical *Haemophilus parainfluenzae* isolate with cefotaxime resistance and decreased susceptibility to fluoroquinolones



Diego Faccone^{a,b}, Paula Lopez-Ruitti^a, Miryam Vazquez^c, Leonor Guerriero^a, Celeste Lucero^a, Paula Gagetti^a, Paola Ceriana^a, Alejandra Corso^{a,*}

^a Servicio Antimicrobianos, National Reference Laboratory, Instituto Nacional de Enfermedades Infecciosas-ANLIS “Dr. Carlos G. Malbrán”, Argentina

^b Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina

^c Hospital General de Niños “Dr. Ricardo Gutiérrez”, Buenos Aires, Argentina

ARTICLE INFO

Article history:

Received 9 February 2016

Received in revised form 2 August 2016

Accepted 3 August 2016

Available online 5 August 2016

Keywords:

Haemophilus parainfluenzae

Cefotaxime

Ciprofloxacin

PBP3

ABSTRACT

We report an *H. parainfluenzae* clinical isolate resistant to cefotaxime and with decreased susceptibility to ciprofloxacin recovered from a patient with cystic fibrosis. The isolate had elevated MICs of ampicillin (256 mg/L), amoxicillin-clavulanate (8 mg/L), cefuroxime (8 mg/L) and cefotaxime (4 mg/L), and showed a β -lactamase-producing amoxicillin-clavulanic acid-resistant (BLPACR) phenotype. A *bla*_{TEM-1} plus five amino acid substitutions in the PBP3 were found: Ser385Thr, Val511Ala, Ile519Val, Asn526Lys and Asp551Leu. MIC of ciprofloxacin was 0.5 mg/L, and substitutions in *gyrA* (Ser84Tyr) and *parC* (Ser84Phe) genes were detected.

© 2016 Elsevier B.V. All rights reserved.

Haemophilus species are considered to be normal inhabitants of the human upper respiratory and urogenital tracts. *H. parainfluenzae* causes opportunistic human infections, mainly associated with respiratory and genitourinary tracts, although severe infections like meningitis, sepsis, septic arthritis, pericarditis and endocarditis were also described (Cardines et al., 2009; Christou et al., 2009; Rodríguez-Martínez et al., 2011; Tinguely et al., 2013). In our country the prevalence of resistance to ampicillin in *H. influenzae* clinical isolates is 22% and mainly associated to β -lactamase production (<http://antimicrobianos.com.ar/2015/?cat=16>).

Decreased susceptibility or resistance to β -lactams in *H. parainfluenzae* can be mediated by the production of TEM β -lactamase, alterations in the penicillin binding protein 3 (PBP3), or the combination of both mechanisms (Tinguely et al., 2013; García-Cobos et al., 2013; Tristram et al., 2008). There are key modifications in PBP3, that were found to reduce the susceptibility against β -lactams, like the amino acid substitutions of Asn for Lys at position 526 or Arg for His at position 517 in the *ftsI* gene of PBP3 (García-Cobos et al., 2013; Tristram et al., 2008; García Cobos et al., 2007). A number of other PBP3 substitutions, in addition to those at positions 526 or 517, that are thought to contribute to decreased susceptibility to β -lactams, are close to the SSN (Ser-385) or the KTG (Val-511 and Ala-530) motifs

that result in elevated MIC to cefotaxime (0.5–1.5 mg/L range) (Tinguely et al., 2013; García-Cobos et al., 2013). Decreased susceptibility (0.12–1 mg/L) or resistance (≥ 2 mg/L) to fluoroquinolones was also reported in *Haemophilus* species being the main mechanism of resistance the acquisition of mutations in the *gyrA* gene with or without mutations in the *parC* gene (Georgiou et al., 1996; Pérez-Vázquez et al., 2004; Law et al., 2010). Fluoroquinolone-resistant *H. parainfluenzae* isolates were recently reported in Spain and Switzerland (Rodríguez-Martínez et al., 2011; Tinguely et al., 2013). Here, we report an *H. parainfluenzae* clinical isolate resistant to cefotaxime and with decreased susceptibility to ciprofloxacin.

H. parainfluenzae M11065 was recovered from the sputum of a fibrocystic two-year old patient in a general hospital from Buenos Aires City, Argentina. The isolate showed an unusual phenotype of resistance to both cefotaxime and ciprofloxacin, therefore it was submitted to the National Reference Laboratory for further characterization. Minimal inhibitory concentration (MIC) was determined by agar dilution using HTM medium, 10^4 CFU/spot, and incubated at 35 °C during 20–24 h in 5% CO₂. MIC was interpreted according to CLSI M100-S25 guidelines (Clinical and Laboratory Standards Institute, 2015). MIC to ciprofloxacin was evaluated with and without 12.5 mg/L of reserpine.

The *ftsI* gene (PBP3) was amplified and sequenced using conditions described by Tristram et al. (Tristram et al., 2008), but with a degenerate forward primer (FtsI-Hp-F1) which was designed in this work (Table 1). Amplification and sequencing of *gyrA*, *parC* and *bla*_{TEM} genes were

* Corresponding author.

E-mail address: acorso@anlis.gov.ar (A. Corso).

Table 1
Primers details, annealing temperatures and product size for specific PCR.

Primer	Gene	Sequence (5'-3')	Annealing (°C)	Product size (bp)
FtsI-Hp-F1	<i>ftsI</i>	GAYGGTGCWCGYGTGTTCTCG	50	1038
FtsI-Hp-R		GCTAGAGAATACCGGGCCAG	50	
<i>gyrA</i> -Hp-F	<i>gyrA</i>	TTCYTACCTTGACTACGCSA	52	441
<i>gyrA</i> -Hp-R		AGTGTCTGGAATACGAGTTGG	52	
<i>parC</i> -Hp-F	<i>parC</i>	CATGGATCGTGCRTTGCCTT	52	471
<i>parC</i> -Hp-R		GTGTGGTGAATATCMGTRG	52	
TEM-Fb	<i>bla_{TEM}</i>	GTATTGCCCGCTCCACGGT	50	1117
TEM-Rb		GAGTAAACTTGGTCTGACAGTTACCA	50	

performed using primers and annealing temperature described in Table 1. PCR reactions were performed using standard conditions (Melano et al., 2003), the elongation step was adjusted to 30 s for *gyrA* and *parC* amplification, and to 60 s for *ftsI* and *bla_{TEM}* genes. Sequences of *ftsI*, *gyrA* and *parC* amplification fragments were compared with sequences of *H. parainfluenzae* T3T1 isolate (Accession NC_015964).

The isolate had elevated MICs of ampicillin (256 mg/L), amoxicillin-clavulanate (8 mg/L), cefuroxime (8 mg/L) and cefotaxime (4 mg/L). β -lactamase production was detected by the nitrocefin assay. The isolate showed a β -lactamase-producing amoxicillin-clavulanic acid-resistant (BLPACR) phenotype according to the susceptibility to β -lactams as defined for *H. influenzae* (Tristram et al., 2007). PCR and sequencing revealed the presence of *bla_{TEM-1}* with a Pdel promoter region which explained the high level of resistance to ampicillin but not to amoxicillin-clavulanate and cephalosporins (Søndergaard & Nørskov-Lauritsen, 2015). Then, five amino acid substitutions were detected in the PBP3: Ser385Thr, Val511Ala, Ile519Val, Asn526Lys and Asp551Leu. To our knowledge, this is the first description of Asp551Leu and Ile519Val modifications in a clinical isolate. The combination of substitutions at positions 385, 511 and 526 were previously described in three *H. parainfluenzae* isolates showing MIC values to cefotaxime between 0.5 and 1.5 mg/L (Table 2) (Tinguely et al., 2013; García-Cobos et al., 2013). *H. parainfluenzae* M11065 presented a third amino acid substitution in position 519 of the KTG motif, in addition to 511 and 526, that could have contributed to the increased cefotaxime MIC value, even though it needs to be confirmed by transformation assays. In this genus, a cefotaxime MIC of 4 mg/L mediated by amino acid substitutions in PBP3, was only described in *H. influenzae* (García Cobos et al., 2007).

Disk diffusion assay to nalidixic acid and ciprofloxacin resulted in no-inhibition zone and a 22 mm inhibition zone, respectively. MIC of

ciprofloxacin was 0.5 mg/L with or without reserpine discarding a possible contribution of efflux pumps to this phenotype. As a result, we detected substitutions in *gyrA* (Ser84Tyr) and *parC* (Ser84Phe) genes. In *H. parainfluenzae* clinical isolates, Ser84Phe amino acid substitution in both *gyrA* and *parC* genes have been the most commonly reported, while the Ser84Tyr mutation in *gyrA* gene were not previously described in this species (Table 2) (Rodríguez-Martínez et al., 2011; Tinguely et al., 2013; Law et al., 2010). Both Ser and Tyr are hydrophilic amino acids, however Tyr has an additional bulky hydrophobic group which could affect the interaction between the DNA gyrase with quinolones. Additionally, we evaluated the presence of plasmid-mediated quinolone-resistance genes by PCR obtaining negative results for *qnrA*, *qnrB*, *qnrS*, *qepA* and *aac-6'-Ib-cr* genes (Andres et al., 2013). The nalidixic acid disk has been previously proposed as a useful screening method to detect decreased susceptibility or resistance to fluoroquinolones in *H. influenzae* (Pérez-Vázquez et al., 2004). In this work, we have observed a good performance of the nalidixic acid disk for *H. parainfluenzae* isolates as well.

β -lactams are first line treatment drugs for Haemophilus infections, therefore the emergence of resistance to cefotaxime is of clinical concern. A recent study documented the intra and interspecies recombination of FtsI in *H. influenzae* and *Haemophilus haemolyticus* *in vitro* resulting in mosaic structure of the gene (Søndergaard et al., 2015). The capacity of *Haemophilus* species to acquire resistance, potentially not only to β -lactams, via mosaic genes, contextualizes the relevance of this report. These facts highlight the importance of antimicrobial surveillance systems to monitor the emergence or increase of resistance in Haemophilus clinical isolates causing infectious diseases.

Funding

This work was supported by the regular federal budget of the National Ministry of Health of Argentina.

Transparency declarations

None to declare.

References

- Andres, P., Lucero, C., Soler-Bistué, A., Guerriero, L., Albornoz, E., Tran, T., Zorreguieta, A., the PMQR Group, Galas, M., Corso, A., Tolmasky, M.E., Petroni, A., 2013. Differential distribution of plasmid-mediated quinolone resistance genes in clinical *Enterobacteria* with unusual phenotypes of quinolone susceptibility from Argentina. *Antimicrob. Agents Chemother.* 57, 2467–2475.

Table 2

Summary of amino acid substitutions described in the *ftsI*, *gyrA* and *parC* genes for *H. parainfluenzae* clinical isolates.

A									
Isolate	β -lactamase	Ser385	Ile442	Val511	Ile519	Asn526	Cefotaxime MIC (mg/L)	Additional substitutions	Reference
M11065	TEM-1	Thr	–	Ala	Val	Lys	4	Asp551Leu	This study
AE-2096513	TEM-1 ^c	Thr	Phe	Ala	–	Lys	1.5	Lys276Asn; Ala307Asn; Val329Ile;	(Tristram et al., 2008)
III-like ^a	None	Thr	Phe	Ala	–	Lys	0.5	Val562Ile	(García-Cobos et al., 2013)
SF2/SF3 ^b	TEM-15 ^d	Thr	–	–	–	His	16/8	Ala343Val;	(Tinguely et al., 2013)
B									
Isolate	<i>gyrA</i>		<i>parC</i>		Ciprofloxacin MIC (mg/L)	Additional substitutions	Reference		
	Ser84	Asp88	Ser84	Tyr88					
M11065	Tyr	–	Phe	–	0.5	None	This study		
617	Phe	Tyr	Phe	–	32	parC: Ser138Thr; Met198Leu	(Rodríguez-Martínez et al., 2011)		
AE-2,096,513	Phe	Tyr	Phe	–	>32	None	(Tinguely et al., 2013)		
07-020	Phe	Tyr	Phe	–	4	None	(Søndergaard & Nørskov-Lauritsen, 2015)		
07-028	Phe	Tyr	Phe	–	12	None	(Søndergaard & Nørskov-Lauritsen, 2015)		

H. parainfluenzae clinical isolates with: decreased susceptibility, MIC 0.5–2 mg/L, or resistance, MIC \geq 4 mg/L, to cefotaxime (panel A); or decreased susceptibility, MIC 0.12–1 mg/L, or resistance, MIC \geq 2 mg/L, to ciprofloxacin (panel B). a, include two isolates with the same β BLNAR group III-like genotype defined in reference 7; b, isolates SF2 and SF3 were indistinguishable by rep-PCR; c, TEM-1 not expressed; d, extended-spectrum TEM β -lactamase.

- Cardines, R., Giufrè, M., ML, C.d.A., Accogli, M., Mastrantonio, P., M., C., 2009. *Haemophilus parainfluenzae* meningitis in an adult associated with acute otitis media. *New Microbiol.* 32, 213–215.
- Christou, L., Economou, G., Zikou, A.K., Saplaoura, K., Argyropoulou, M.I., Tsianos, E.V., 2009. Acute *Haemophilus parainfluenzae* endocarditis: a case report. *J. Med. Case Rep.* 3, 7494.
- Clinical and Laboratory Standards Institute, 2015. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S25. CLSI, Wayne, PA, USA.
- García Cobos, S., Campos, J., Lázaro, E., Román, F., Cercenado, E., García-Rey, C., Pérez-Vázquez, M., Oteo, J., de Abajo, F., 2007. Ampicillin-resistant non- β -lactamase-producing *Haemophilus influenzae* in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. *Antimicrob. Agents Chemother.* 51, 2564–2573.
- García-Cobos, S., Arroyo, M., Campos, J., et al., 2013. Novel mechanisms of resistance to β -lactam antibiotics in *Haemophilus parainfluenzae*: β -lactamase-negative ampicillin resistance and inhibitor-resistant TEM β -lactamases. *J. Antimicrob. Chemother.* 68, 1054–1059.
- Georgiou, M., Muñoz, R., Román, F., Cantón, R., Gomez-Lus, R., Campos, J., De La Campa, A., 1996. Ciprofloxacin-resistant *Haemophilus influenzae* strains possess mutations in analogous positions of GyrA and ParC. *Antimicrob. Agents Chemother.* 40, 1741–1744.
- Law, D.K.S., Shuel, M., Bekal, S., Bryce, E., Tsang, R.S.W., 2010. Genetic detection of quinolone resistance in *Haemophilus parainfluenzae*: mutations in the quinolone resistance-determining regions of gyrA and parC. *Can. J. Infect. Dis. Med. Microbiol.* 21, e20–e22.
- Melano, R., Corso, A., Petroni, A., Centrón, D., Orman, B., Pereyra, A., Moreno, N., Galas, M., 2003. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β -lactamases in a *Klebsiella pneumoniae* clinical strain isolated in Argentina. *J. Antimicrob. Chemother.* 52, 36–42.
- Pérez-Vázquez, M., Román, F., Aracil, B., Cantón, R., Campos, J., 2004. Laboratory detection of *Haemophilus influenzae* with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to gyrA and parC mutations. *J. Clin. Microbiol.* 42, 1185–1191.
- Rodríguez-Martínez, J.M., López-Hernández, I., Pascual, A., 2011. Molecular characterization of high-level fluoroquinolone resistance in a clinical isolate of *Haemophilus parainfluenzae*. *J. Antimicrob. Chemother.* 66, 673–675.
- Søndergaard, A., Nørskov-Lauritsen, N., 2015. Contribution of PBP3 substitutions and TEM-1, TEM-15, and ROB-1 Beta-lactamases to cefotaxime resistance in *Haemophilus influenzae* and *Haemophilus parainfluenzae*. *Microb. Drug Resist.* <http://dx.doi.org/10.1089/mdr.2015.0189>.
- Søndergaard, A., Witherden, E., Nørskov-Lauritsen, N., Tristram, S.G., 2015. Interspecies transfer of the penicillin-binding protein 3-encoding Gene *ftsI* between *Haemophilus influenzae* and *Haemophilus haemolyticus* can confer reduced susceptibility to β -lactam antimicrobial agents. *Antimicrob. Agents Chemother.* 59, 4339–4342.
- Tinguely, R., Seiffert, S.N., Furrer, H., et al., 2013. Emergence of extensively drug-resistant *Haemophilus parainfluenzae* in Switzerland. *Antimicrob. Agents Chemother.* 57, 2867–2869.
- Tristram, S., Jacobs, M.R., Appelbaum, P.C., 2007. Antimicrobial resistance in *Haemophilus influenzae*. *Clin. Microbiol. Rev.* 20, 368–389.
- Tristram, S.G., Pitout, M.J., Forward, K., Campbell, S., Nichols, S., Davidson, R.J., 2008. Characterization of extended-spectrum β -lactamase-producing isolates of *Haemophilus parainfluenzae*. *J. Antimicrob. Chemother.* 61, 509–514.